Coherus Oncology, Inc. (CHRS) Q4 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good day and thank you for standing by. Welcome to the Q4 and full year 2025 Coherus Oncology Inc. Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during the session, you will need to press star 1, 1 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press star 1, 1 again. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker today, Carrie Graham. Please go ahead. Thank you, Heidi. Good afternoon, and welcome to Hill-Harris Oncology's fourth quarter and 2025 year-end earnings conference call. Joining me today to discuss our results are Denny Lansfair, Chief Executive Officer of Hill-Harris, Dr. Teresa Lavallee, Chief Scientific and Development Officer, Dr. Rosh Gaius, Chief Medical Officer, Samira Gorizoker, Chief Commercial Officer, and Brian McMichael, Chief Financial Officer. Before we get started, I would like to remind you that today's call includes forward-looking statements regarding O'Hara's current expectations about future events. Actual results may vary significantly, and we undertake no duty to update or revise any forward-looking statements. Please see the press release that we issued today and our annual report on Form 10-A for more information on risks and uncertainties. And now I'll turn the call over to Denny. Thank you, Carrie, and thank you all for joining us today on our Q4 2025 call and our 2025 Annual Summary to Investors. This was a year in which we completed our strategic transformation to an innovative oncology company focused on overcoming immune resistance in cancer. This ...